Ohio State biotech spinoff Entrada raises $59M to tackle deadly disease with no other treatment
An Ohio State University spinoff developing a treatment for a deadly mitochondrial disease launched Tuesday in Boston with a $59 million round of venture capital investment.
Entrada Therapeutics is using science developed by Ohio State University professor and company co-founder Dehua Pei to deliver treatment to previously un-druggable targets in the power center of a cell.
The Series A investment announced Tuesday is the largest ever for an OSU spinoff, the school said.
“Our commitment to…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Allison DeAngelis Source Type: news